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ABSTRACT    
 
INTRODUCTION: Chronic kidney disease-mineral and bone disorders (CKD-MBD) 
are associated with costly complications and dismal hard-outcomes. 
AREAS COVERED: In two comprehensive articles we review contemporary and 
future pharmacological options for treatment of phosphate (P) imbalance (part 1) and 
hyperparathyroidism (this part 2), taking into account CKD-accelerated cardiovascular 
calcification (CVC) processes.  
EXPERT OPINION: Improvements in CKD-MBD require an integral approach, 
addressing all three components of the CKD-MBD triad. Here, initial guidance to 
control hyperparathyroidism is provided, taking into account the presence/absence of 
CVC. We include also measures for patients at risk of adynamic bone disease or 
suffering from calciphylaxis. Many epidemiological studies (relating to vitamin D) and 
thorough analyses of recent randomized clinical trials (of cinacalcet) point towards 
benefits of attempting to improve biochemical parameters while trying to, at least, avoid 
progression of CVC by more rational use of intestinal P-binders and low-dose vitamin 
D derivatives and/or calcimimetics. This approach does not seem to be far away from 
significantly improving hard-outcomes, at least in the dialysis population. The 
availability of new drugs and the performance of randomized clinical trials should 
ultimately lead to define earlier, clearer, and more cost-effective patient stratification 
and biochemical targets with consequent significant clinical improvements. 
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1) INTRODUCTION 
As previously mentioned in part 1 of this review1, accelerated atherosclerosis 
and premature ageing are closely associated with chronic kidney disease (CKD) and 
particularly with end-stage renal disease (ESRD)2–5. The term chronic kidney disease-
mineral and bone disorder (CKD-MBD) was introduced eleven years ago to define a 
triad of laboratory and bone abnormalities and tissue (mainly vascular) calcifications, all 
of which are linked to poor hard-outcomes 6,7. Currently, bone is considered a new 
endocrine organ at the heart of CKD-MBD, while there is ongoing controversy as to 
whether CKD-MBD should be regarded as a real syndrome or not8,9. 
The increasing availability of new phosphate (P)-binders (reviewed in reference 
1), vitamin D (VD) receptor activators (VDRA) and the innovative development of 
modulators of the calcium (Ca)-sensing receptor (CaSR) –calcimimetics- have 
significantly increased our therapeutic armamentarium10,11. Furthermore, the appearance 
of sevelamer and recognition of the fibroblast growth factor-23 (FGF23)/klotho axis 
have helped to review paradigms in the pathophysiology of secondary 
hyperparathyroidism (SHPT)12,13, and to increase awareness of the presence of 
cardiovascular calcification (CVC) and the need to quantify it14,15. These developments 
have given rise to the concept that CKD-MBD-related drugs such as non-Ca-based P-
binders may attenuate the accelerated progression of CVC in CKD patients and 
potentially improve survival15–18. Consequently, other agents such as anti-parathyroid 
drugs have also been analyzed in this regard. 
In order to control the increasing parathyroid hormone (PTH) levels, new VDRA 
and calcimimetics were introduced that allowed not only medical treatment of 
previously calcitriol-resistant patients with severe forms of SHPT19 but also earlier and 
more effective control of CKD-MBD-related laboratory parameters. Experimental and 
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clinical studies have also shown that some anti-parathyroid agents may attenuate the 
progression of CVC20,21, potentially leading to improved survival22–24. The number of 
parathyroidectomies (PTX) has also markedly dropped25,26, and it should not be 
forgotten that PTX (and PTX-related percutaneous injections of ethanol or VD in 
parathyroid glands) are not exempt from important risks, especially in the perioperative 
period and during the year after the procedure27, including permanent 
hypoparathyroidism.  
Against this background, the purpose of this article is to provide an update on 
the contemporary pharmacological control of PTH in the context of CKD-MBD. The 
first part focused on agents that aim to control P imbalance and this second part covers 
anti-parathyroid drugs such as VD derivatives and calcimimetics emphasizing their 
differential effects not only on biochemical parameters but also on tolerance, CVC, 
and/or hard-outcomes. Related issues such as the very frequent adynamic bone disease 
(ABD), usually neglected in drug -reviews, and the rare calciphylaxis will also be 
briefly discussed.   
 
2) VITAMIN D 
SHPT is a common consequence of CKD, which not only leads to bone disease 
but also plays a role in reducing quality of life and increasing mortality of CKD patients28–
31. Calcitriol (1,25-(OH)2-VD), as an anti-parathyroid agent, decreases the synthesis of 
PTH independently of its known hypercalcemic action by acting through its specific 
receptor (the VD receptor)32. The desirable serum PTH target levels and the variability of 
PTH assays are matters of intense current debate7,33–38. For instance, Kidney Disease 
Improving Global Outcomes (KDIGO) guidelines suggest that in CKD stage 5 and 5D, 
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serum PTH levels should be maintained at between 2 and 9 times (2X-9X) the upper 
normal limits for the used assay7, based on the poor quality as a biomarker of PTH in 
relation to underlying renal bone disease7,36. Other national guidelines continue to support 
the 2003 National Kidney Foundation (NKF)/Kidney Dialysis Outcomes Quality 
Initiative (KDOQI™) recommendation of 150-300 pg/ml (2X-5X)39,40,35, mainly based 
on some epidemiological studies describing the lowest mortality rates in this PTH interval 
30,31. Agreement exists regarding the need for treatment when laboratory values  show an 
increasing trend over time, even within the aforementioned ranges, and the fact that values 
exceeding 9 times the upper normal limit must be avoided because they represent 
extremes of risk7,34,39. As a matter of fact, questions remain about the wide PTH range 
suggested in the KDIGO guidelines26,36, and there is concern that the acceptance of “very 
high” values may negatively impact bone quality, result in the progression of parathyroid 
glands to uncontrollable monoclonal-growth tumor-like nodular hyperplasia and decrease 
the efficacy of treatment strategies36. In this respect, it is well known that higher than 
normal serum PTH levels are required to maintain bone remodelling in CKD due to the 
presence of resistance to the action of PTH41, while PTH levels above the 150-300 pg/ml 
range are associated with increases in hospitalizations26,29 , fractures29,42,43 and, as 
mentioned before,  mortality rates30,31.  
Recent changes in therapeutic approaches and their impact on outcomes among 
patients with SHPT on chronic hemodialysis have been described by Tentori et al26. Using 
data from the international Dialysis Outcomes and Practice Patterns Study (DOPPS), 
these authors analyzed trends in PTH levels and SHPT therapies over the past 15 years 
and studied the associations between PTH and clinical outcomes. A total of 35,655 
participants from the DOPPS phases 1-4 (1996-2011) were included, and it was found 
that median PTH increased from phase 1 to phase 4 in all regions except Japan, where it 
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remained stable. Importantly, compared with the 150-300 pg/ml range, in adjusted models 
all-cause mortality risk was higher for PTH=301-450 pg/ml (hazard ratio, 1.09; 95% CI, 
1.01-1.18) and >600 pg/ml (hazard ratio, 1.23; 95% CI, 1.12-1.34). PTH >600 pg/ml was 
also associated with a higher risk of cardiovascular mortality and all-cause and 
cardiovascular hospitalizations. Prescriptions of intravenous VDRA (and cinacalcet) 
increased and PTX rates decreased in all regions over time. In a subgroup analysis of 
5,387 patients not receiving anti-parathyroid agents and without prior PTX, very low 
serum PTH levels (<50 pg/ml) were associated with increased mortality risk (hazard ratio, 
1.25; 95% confidence interval, 1.04-1.51).  
On the other hand, there are also serious concerns about normalizing serum PTH 
levels in CKD stages 3-5 since moderate elevations of PTH may serve as a beneficial 
adaptive response (with improvements in phosphaturia or bone turnover)36. All these 
results underline the urgent need for additional research into PTH targets, both in dialysis 
and non-dialysis patients, as well as the concomitant use of other risk factors and 
biomarkers in order to better define appropriately individualized clinical practice. Thus, 
it seems clear that old protocols using just serum PTH levels for correlation with bone 
turnover and/or survival are inadequate in terms of sensitivity and specificity. Other 
factors such as Ca, P, CVC should also be taken into account; nevertheless, in patients 
with CKD and elevated or rising PTH, it is still suggested that VD derivatives, 
calcimimetics or a combination thereof may be used to lower PTH (evidence 2B)7. 
Monitoring of alkaline phosphatase activity (especially bone-specific) in combination 
with PTH may also be helpful to increase specificity44,45. 
 2.1) NATIVE VITAMIN D  
It is well known that VD deficiency is common both in the general population 
and in patients with CKD46,47. It is usually due, among other factors, to inadequate 
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exposure to sunlight and/or a VD deficient diet. The importance of its diagnosis has 
been increasingly recognized because of the reported association between circulating 
calcidiol levels [25-(OH)-VD, the storage form of VD] and survival in both the general 
population and dialysis patients48,49. In fact, many beneficial pleiotropic effects beyond 
bone have been attributed to VD and VD receptor activation, including with regard to 
CKD-MBD laboratory markers, inflammation and even risk of falls (if high doses are 
avoided)50,51. However, to date no definitive proof is available regarding a benefit for 
hard-outcomes, although the use of cholecalciferol (VD3), or ergocalciferol (VD2) (real 
forms of “native” VD) and 25-(OH)-VD supplementation have been shown to be able to 
correct calcidiol levels in CKD patients, including those receiving dialysis52,53. Thus, 
calcidiol measurement (and supplementation in deficient states) is recommended for 
CKD patients in most guidelines5,7,39,40. In a retrospective study, treatment with active 
forms of VD significantly abolished the relationship between survival and calcidiol 
levels48, and thereby the significance of calcidiol levels in patients treated with active 
forms of VD remains unclear. The dual combination of cholecalciferol and active VD 
(e.g. paricalcitol) has also been safely tested in hemodialysis patients54. Finally, 
traditional measures of VD status may need to be revisited to account for levels of VD-
binding protein and albumin (“bioavailable VD”), since both can bind circulating VD55. 
 
2.2) CALCITRIOL  AND SELECTIVE VDRA   
In CKD, the synthesis of calcitriol by 1-α-hydroxylase is limited by the dual 
inhibitory and catabolic effect of elevated FGF23 levels and the progressive reduction in 
renal mass, contributing to the development and progression of SHPT. Calcitriol is also 
needed to improve the cellular uptake of calcidiol56. Consequently, 1-α-hydroxylated 
alfacalcidol and doxercalciferol (1-α-VD3 and 1-α-VD2 pro-hormones, respectively) and 
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the physiologically active calcitriol represent classical elements of the strategy to 
prevent and control uremic SHPT. Survival benefits have been consistently associated 
with the use of different active VD compounds in retrospective studies in CKD, 
including dialysis patients and even patients with low PTH levels57–60, highlighting the 
importance of VDR activation in CKD. Nevertheless, there is still the possibility that 
unrecognized confounding variables may account for the observed benefits, and the lack 
of prospective trials diminishes the strength of these results. On the other hand, high 
doses of VDRA may cause increased serum Ca and P levels, especially in patients with 
ABD, and increased CVC has commonly been demonstrated in experimental animals 
with CKD fed high P diets20,61,62. Selective VDRA (e.g., paricalcitol or maxacalcitol) 
seem to have more selective effects on the parathyroid glands as compared with bone 
and the gastrointestinal (GI) tract (decreasing the risk of high serum Ca, Ca x P, and/or 
P levels)63–65, as well as reduced experimental procalcifying effects on vessels20,61,62, 
thereby theoretically providing a wider therapeutic window as compared with 
calcitriol63. Clinical improvement of endothelial function has also been shown in a small 
randomized controlled trial (RCT) in which patients with stage 3-4 CKD were treated 
with paricalcitol (vs placebo)66. Nevertheless, it has to be recognized that despite the 
robustness of the data regarding the beneficial clinical effects of VD, including 
experimental restoration of klotho, clinical improvement of residual proteinuria in RCTs 
and meta-analyses, and improved survival in retrospective studies and meta-analyses67–
70, hard-outcome benefits have not been proven and no positive effects on left 
ventricular hypertrophy have been demonstrated in RCTs (secondary or post-hoc 
analyses only)71–73. Moreover, distinctions among specific vitamin D compounds 
remain a matter of great controversy20,68,74,75. 
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 2.3) NEW VDRA  
Several VDRA for the treatment of SHPT are in the early stages of development 
(i.e. CTAP101, CTAP201, 2MD, CTA018/MT2832, CTA091)10,76. CTAP101, a 
modified-release capsule formulation of calcifediol, has been designed to raise serum 
25-(OH)-VD in a gradual manner to physiological levels, avoiding excessive induction 
of CYP24; it has now reached Phase III development in CKD patients with vitamin D 
insufficiency77. Results from a Phase I trial of intravenous CTAP201 in hemodialysis 
patients revealed decreased PTH levels similar to those obtained with doxercalciferol 
but with lower serum Ca and P levels10,78. 
Although developed for osteoporosis treatment, 2MD demonstrated reduction of 
PTH levels without concomitant increases in serum Ca and P in both preclinical and 
postmenopausal women79. Lunacalcipol (CTA018/MT2832) is the first compound in a 
new class of vitamin D hormone analogs having a novel dual mechanism of action. 
(http://www.prnewswire.com/news-releases/cytochroma-regains-rights-to-lunacalcipol-
156261375.html). Similarly to other compounds such as CTA091, it is a potent CYP24 
inhibitor (increasing the half-life of active VD by decreasing its clearance)76. 
Lunacalcipol differs from CTA091 in that it also has the ability to activate VDR-
mediated transcription and suppresses PTH synthesis at doses which do not affect 
experimental Ca and P levels76. However, changes in US market dynamics relating to 
dialysis treatment seem to delay its clinical development. 
 
3) CALCIMIMETICS.  
 3.1) CINACALCET 
As mentioned before, most traditional therapies for SHPT have entailed 
correction of reduced Ca intake and absorption in CKD patients, correction of 
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hypocalcemia and excessive production of PTH by administration of Ca salts,  
supraphysiological Ca levels in the dialysate, use of VDRA, and prevention of 
hyperphosphatemia by means of Ca-based P-binders1,80. However, these therapies have 
been limited by the occurrence of hyperphosphatemia (VDRA) and hypercalcemia, a 
lack of specificity, restricted long-term efficacy, and potential vascular toxicity11,24,81 . 
On the other hand, surgical PTX is not exempt from risks27. The identification and 
cloning of CaSR in the 1990’s prompted the development of calcimimetics and 
calcilytic agents82. Cinacalcet, the first clinically available activator of the CaSR 
(calcimimetic), represents a completely new mechanism of action and extends the 
armamentarium against SHPT in dialysis patients and primary hyperparathyroidism24,83 
(Table 1).  
It has been shown that cinacalcet, when tolerated, is very effective in reducing 
abnormal circulating levels of PTH, Ca, P, CaxP product and, importantly, 
FGF2324,81,84. Furthermore, two important prospective RCTs evaluated both the efficacy 
of cinacalcet in preventing the progression of CVC (ADVANCE)21 and its effect on all-
cause mortality and cardiovascular events (EVOLVE)22. First, the ADVANCE trial 
suggested that cinacalcet plus low doses of VD may attenuate the progression of 
coronary, aortic, and valvular calcification compared with flexible VD therapy21. 
Although significant changes in the volume of coronary artery calcifications were 
described, results with respect to the predefined primary end-point of the study (surface) 
did not strictly reach statistical significance (p=0.07). Two recent post-hoc analyses 
suggested that cardiac valve calcification was a predictor of coronary artery 
calcification progression and, potentially, of greater cardiovascular vulnerability85 and 
demonstrated that treatment with cinacalcet had statistically significant beneficial 
effects among participants who adhered to the prespecified protocol86. Second, the 
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EVOLVE RCT did not reach its primary composite end-point (all-cause mortality and 
cardiovascular events) after an unadjusted intention to-treat (ITT)–based analysis22. 
These results were supported by a recent meta-analysis, mainly driven by this negative 
EVOLVE primary result, which included other heterogeneous studies with different 
designs87. However, we do believe that it is important to emphasize that prespecified 
secondary ITT adjusted analysis revealed a nominally significant improvement in 
survival in the cinacalcet group24,22. Thus, the effect of cinacalcet was significantly 
more pronounced among patients aged ≥65 years in secondary and post-hoc 
analyses22,88. Lag-censoring and other prespecified companion analyses also suggested a 
nominally significant beneficial effect of cinacalcet on the primary composite end-
point22, and accepting the limitations of non-primary analysis, patients randomized to 
cinacalcet experienced fewer non-atherosclerotic cardiovascular events (including 
sudden death and heart failure), a decreased incidence of PTX, fewer episodes of 
calciphylaxis, and a reduction in clinically-reported fractures22,23,89. The excessive rate 
of drop-ins and drop-outs and the loss of statistical power, among other factors, 
probably seriously hindered the interpretation of the primary end-point and rendered the 
EVOLVE study inconclusive24. Consequently, cinacalcet may not be warranted in all 
dialysis patients and it cannot be recommended in order to improve their survival90; 
however,  it unquestionably improves the achievement of target levels for all metabolic 
abnormalities associated with CKD-MBD and mortality91,92. A summary of negative 
and positive aspects of the EVOLVE study is presented in Table 2.  
  It has been recently reviewed the practical use of calcimimetics in dialysis 
patients assessing and advising how to circumvent the most frequent adverse events 
such as nausea and vomiting (Table 3), hypocalcemia, PTH oversuppression and QT-
prolongation, among others, with the goal of potentially improving clinical practice and 
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patient adherence24. Beyond the influence of cost in prescription rates93, persistence of 
treatment among patients remains low despite all the beneficial effects associated with 
cinacalcet93,92,94. 
 
3.2) ETELCALCETIDE (AMG416)    
Etelcalcetide (AMG416 or, as previously confusingly named, velcalcetide) is 
currently in development and undergoing regulatory review. It represents a novel, third 
generation intravenous (i.v.) long-acting selective peptide agonist of the CaSR95,96. 
Etelcalcetide allows i.v. administration in the dialysis setting and may improve drug 
monitoring and adherence. A multicenter, double-blind, placebo-controlled, dose-
escalation study designed to evaluate the safety and efficacy of etelcalcetide 
administered thrice weekly by i.v. bolus at the end of hemodialysis for up to 4 weeks for 
the treatment of SHPT in hemodialysis patients has recently been published97. It was 
observed that a substantial proportion of subjects treated with etelcalcetide achieved 
PTH ≤300 pg/mL and a ≥30% reduction in PTH from baseline, supporting the 
continued development of etelcalcetide. The observed decreases in serum-corrected Ca 
were well tolerated and serum P levels also tended to decrease. Etelcalcetide 
pharmacokinetics have also been recently published98. 
The results of a second  placebo-controlled Phase III study in dialysis patients 
evaluating the effect of etelcalcetide on the treatment of SHPT were recently 
announced99,100. The study’s primary endpoint was the proportion of patients with a > 
30% reduction from baseline in PTH levels during an efficacy assessment phase defined 
as weeks 20-27 of the study. In the etelcalcetide group, 74% of patients achieved the 
primary endpoint, compared with 8.3% of patients in the placebo group. Secondary 
endpoints included the percentage change in serum P (-7.7% and -1.3% in the 
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etelcalcetide and placebo arms, respectively) and corrected Ca concentrations (-7.3% 
and 1.2%, respectively). Both of these secondary endpoint results were statistically 
significant. Treatment-emergent adverse events were reported in 92% of patients who 
received etelcalcetide and 79% of patients receiving placebo. The most frequently 
reported adverse event was asymptomatic reduction in Ca; symptomatic hypocalcemia 
was reported in 7.2% of patients who received etelcalcetide compared with 0.4% in the 
placebo group 100. The proportions of patients reporting muscle spasms, diarrhea, 
nausea, and vomiting were higher in the etelcalcetide group than in the placebo group 
99,100. 
Another Phase III, head-to-head, double-dummy, placebo-controlled study of 
etelcalcetide and cinacalcet  has also been conducted to compare their efficacy and    
tolerability. It has been announced that treatment with i.v. etelcalcetide achieved >50%  
and >30% reductions in PTH in more patients compared with cinacalcet, while, 
somewhat surprisingly, nausea and vomiting did not seem to differ101.  Thus, it is 
currently unclear whether etelcalcetide will have fewer adverse GI effects compared 
with oral cinacalcet. The i.v. route may also offer a potential reduction in the risk of 
drug-drug interactions96. A numerical imbalance in cardiac failure was observed in this 
study, for which a causal relationship to etelcacetide could not be established101. 
Hypocalcemia was seen more frequently with etelcalcetide and the safety profiles 
appeared to be comparable although more prolonged clinical experience is definitely 
required101.  
 
3.3) NEW CALCIMIMETICS 
Two other oral CaSR modulators are in Phase II development (KHK-7580 and 
ASP7991)10. ASP7991 has been shown to significantly decrease PTH levels in a rat 
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model of SHPT and may have less potential for CYP-enzyme-mediated drug-drug 
interactions than cinacalcet10. Another calcimimetic compound, LEO 27847, has been 
evaluated in a Phase I study for the treatment of SHPT, but no additional information 
regarding its development is available10. 
 
4) ADYNAMIC BONE DISEASE 
Adynamic bone disease (ABD) is a well-recognized clinical entity in the CKD-
MBD complex102,103. Although the gold-standard diagnostic method is bone biopsy, the 
presence of low circulating PTH and low bone-specific alkaline phosphatase levels may 
be suggestive of ABD44. In the most recent bone histomorphormetry study before and 
after long-term treatment with an antiparathyroid agent (cinacalcet), no ABD was 
observed among patients with PTH ≥ 300 pg/ml, Ca ≥ 8.4 mg/dl and bone-specific 
alkaline phosphatase > 20.9 ng/ml, although 22 out of 146 patients had normal bone 
histology45. 
ABD is increasing in prevalence relative to other forms of renal osteodystrophy 
and is becoming the most frequent type of bone lesion in some series7,102 It is potentially 
linked to fracture risk and progression of CVC. Among many other factors (recently 
reviewed in reference 103), drug-induced oversuppression of PTH may contribute to this 
low-turnover bone state45. Thus, prevention of sustained PTH levels <2 times the upper 
limit of normality, especially in the steadily growing proportions of diabetic, white, and 
elderly patients, is of the outmost importance (Table 4). In the recent COSMOS study, in 
patients with baseline PTH levels below 168 pg/ml (mean 89 pg/ml), increases in PTH 
were associated with a lower risk of mortality34. Recombinant PTH has been used in case-
reports104. The potential use of Natpara®, released to control hypocalcemia in patients 
with hypoparathyroidism, or antisclerostin monoclonal antibodies remains to be tested103. 
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5) CALCIPHYLAXIS   
Calciphylaxis, or calcific uremic arteriolopathy, is a rare condition and continues 
to represent a clinical challenge105,106. In addition to existing pharmacological 
treatments, and that cinacalcet appears to reduce the incidence of calciphylaxis in 
hemodialysis patients107, sodium thiosulfate has recently been introduced in the 
armamentarium against calciphylaxis. It may also attenuate the rate of progression of 
CVC but at the expense of reduced bone mineral density at the hip108. Vitamin K 
deficiency is common in ESRD, and vitamin K antagonists (e.g. warfarin) may promote 
calciphylaxis as well as CVC109. Thus, several prospective RCTs are currently 
evaluating the effect of vitamin K supplementation on the progression of CVC110. 
Beyond osteoporosis treatment, different bisphosphonates have also been used off-label 
in the treatment of calciphylaxis; however, since their potentially positive effects on 
CVC cannot be separated from an adequate bone formation, administration of these 
drugs to patients with CKD stage 4/5 may be unsafe7. A novel approach with an i.v. 
formulation (SNF472) of myo-inositol-hexaphosphate (phytate), a selective 
calcification inhibitor, is being developed as an orphan drug, and Phase II studies are 
being developed to analyze its influence on the progression of CVC in dialysis patients 
111.  
6) CONCLUSION 
Improvements in the management of CKD-MBD require an integral approach 
that addresses all 3 components of the CKD-MBD triad. Individualization of P-binders 
and reasonable combinations of anti-parathyroid agents may provide the best 
biochemical control with the lowest incidence of undesirable effects. Despite the 
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absence of level 1A evidences from RCTs on whether any treatment or a combination of 
treatments should be preferred in order to control CKD-MBD81,90 and the lack of 
consensus among nephrologists on the best diagnostic parameters or treatment 
laboratory goals, there is general agreement that CKD-MBD and SHPT are common 
and costly manifestations of CKD. Clear associations with negative quality of life, 
CVC, cardiovascular complications, and worse patient outcomes have been repeatedly 
reported.  
We have already mentioned that avoidance of an excessive P load is currently 
considered one of the key issues in the management of CKD-MBD1. We also previously 
reported that best treatment remains to be defined, especially considering the low 
efficiency, poor patient adherence, potential toxicity and cost of P-binders1. Retail 
prices are currently decreasing due to the advent of generic drugs after expiry of patent 
protection, and this may change some subjective perceptions.  
In this second part of the article we have reviewed specific anti-parathyroid 
treatment, including several VDRA (some of which are described as selective VDRA), 
calcimimetics, and combinations thereof. Guidelines suggest that VDRA treatment may 
be used in patients with stage 3-5 CKD who are not on dialysis and in whom PTH is 
progressively rising and remains persistently above the upper limit of normal for the 
assay despite correction of modifiable factors. On the other hand, VDRA and/or 
calcimimetics are suggested in patients with CKD stage 5D and elevated or rising PTH, 
bearing in mind that it is reasonable for the initial drug selection to be based on Ca and 
P levels as well as on other aspects of CKD-MBD such as cardiovascular calcification. 
Determination of CVC fits into the paradigm of personalized medicine112, and 
we believe that an assessment for CVC is therefore warranted at least in some patients, 
including any in whom the carying physician decides that knowledge of the presence of 
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CVC may impact therapeutic decisions (i.e., Ca- vs non-Ca based P-binders; calcitriol 
or alfacalcidol vs paricalcitol or maxacalcitol; VDRA vs calcimimetics)1,112,113. 
Actually, in the recent commentary from a KDIGO controversies conference36, it was 
stated that “the group was unanimous in their assessment of the clinical significance of 
cardiovascular calcification and the conclusion that cardiovascular calcification should 
be considered for guidance of CKD-MBD management”. 
Although the link between intervention and outcomes when progression of CVC 
is attenuated has not been conclusively demonstrated, cheap and readily accessible plain 
X-rays and/or echocardiography may help to define the initial best and safest 
treatments, at least until we are able to use other therapeutic means at earlier stages of 
the accelerated atheromatosis process112,114.   
7) EXPERT OPINION 
PTH is a poor biomarker in relation to underlying bone disease, at least partially 
due to the presence of multifactorial resistance to the renal and skeletal actions of PTH 
in uremia and the variability of PTH assays. For the moment and until deciphering the 
way to circumvent these problems, it is clear that serum PTH levels should be 
maintained higher than normal in dialysis patients. Thus, KDIGO guidelines suggest 
that ”serum PTH levels should be maintained at between 2X-9X the upper normal limits 
for the used assay” in patients with CKD stage 5D; nevertheless, we follow the Spanish 
adaptation of the KDIGO guidelines which initially aim at 2-5 times the upper limit of 
normality to free up space and safely avoid KDIGO extremes of risk (<2 or >9 times the 
upper normal limit) 35,39,40.  This narrower PTH interval has been chosen from some 
important epidemiological studies describing that the lowest mortality rates in dialysis 
patients are found in this PTH range26,30,31. Nephrologists should not react to any minor 
PTH variation by instituting “urgent” changes in treatment. On the other hand,  there are 
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also serious concerns about normalizing serum PTH levels in CKD stages 3-5 since 
moderate elevations of PTH may serve as a beneficial adaptive response (with 
improvements in phosphaturia or  bone turnover)36.  
 VD receptor is ubiquitous and can be directly or indirectly activated by different 
forms of native and active VD . We usually supplement with native vitamin D as 
suggested in different guidelines, using treatment goals and strategies recommended for 
the general population. Many beneficial pleiotropic global class effects have been 
described for active forms of VD, including survival benefits in observational studies 
and meta-analyses. Selective VDR activation, identified by its low calcemic, low 
phosphatemic profile, may yield specific differential beneficial effects at the tissue and 
molecular levels (e.g. slower CVC progression), but this has only been shown under 
experimental conditions, and no RCT has ever been performed.  We believe that 
although it has not been proven that VDRA improve hard-outcomes, it would be 
insensitive to completely dismiss the accumulated robust data. In this regard, 
paricalcitol shares, and sometimes has been shown to selectively improves, pleiotropic 
VD-related systemic effects68,75. Questions about costs in relation to benefits may be 
raised, but it is to be borne in mind that expiry of patent protection will decrease retail 
prices. 
Practical issues regarding the use of VDRA have recently been reported115,116. 
Briefly, we use paricalcitol as the first-line VDRA due to its wider therapeutic window 
as compared with calcitriol, especially in patients with CVC, diabetics, and patients 
treated with coumadin derivatives. In adults, in order to avoid unacceptably and 
unnecessarily rapid PTH suppression, we calculate the initial dose based on baseline 
serum intact PTH (iPTH) levels (µg of paricalcitol iv /dialysis session = baseline iPTH 
in pg/mL / 100-120) instead of the common iPTH/80 reported in the summary of 
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product characteristics. Conversion of intravenous paricalcitol from calcitriol is 
smoother using a 1:3 calcitriol to paricalcitol conversion ratio117. In patients not 
undergoing dialysis, we usually convert oral calcitriol to paricalcitol on a 1:4 basis 
according to the most commonly marketed dose (0.25 µg of calcitriol/1 µg of 
paricalcitol). Further dose adjustment is necessary according to PTH response and 
during the concomitant use of calcimimetics (in dialysis patients). We generally prefer 
non-Ca-based P-binders, especially when using VDRA; while VDRA and/or 
paricalcitol may be administered with Ca-based P-binders, there is an increased risk of 
hypercalcemia and, potentially, progression of CVC20,81. If not a first choice, cinacalcet 
may be used as a rescue drug in the event of hypercalcemia118. 
On the other hand, the use of cinacalcet is fully justiﬁed at least as a component 
of a multitargeted intervention in dialysis patients with SHPT, including P-binders and 
VD. Among patients with hypercalcemia or significant hyperphosphatemia, 
calcimimetics are probably the best first-line treatment since hypercalcemia and 
hyperphosphatemia occur more often with VDRAs7,81,119. Calcimimetics should not be 
started if basal serum Ca level is less than 8.4 mg/dl but mild hypocalcemia is clinically 
acceptable during the maintenance phase (normality for Ca levels will probably be soon 
revisited by KDIGO in patients treated with calcimimetics)36.  In any case, in order to 
avoid unnecesary positive Ca balances, Ca should not be pushed up when patients 
develop assymptomatic mild hypocalcemia (i.e. 8.0 mg/dl), especially if no significant 
changes are observed in the QT-interval. Calcimimetics may also allow a safer 
concomitant use of VDRA, benefiting patients as a result of their credited pleiotropic 
effects. Crossed positive, bidirectional and additive interactions between calcimimetics 
and VDRA have been described in experimental studies120,121. An important difference 
between calcimimetics and VDRA is that two important RCTs relating to the former at 
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least show a nominally significant benefit over standard therapy with respect to hard-
outcomes in dialysis patients. Emerging i.v. calcimimetics may promote patient 
compliance and improve achievement of treatment goals. On the other hand, various 
maneuvers, including decreasing or withdrawing Ca-based P-binders, VD derivatives 
and/or calcimimetics as well as decreasing the dialysate-bath Ca content will help to 
increase PTH levels to safer levels in those patients at risk of ABD.  
Finally, many believe that a combination of P-binders and a combination of anti-
parathyroid agents is probably the best current clinical option, as in other areas of 
Nephrology such as the treatment of hypertension or albuminuria and the use of 
immunosuppressive protocols in transplantation (Table 5). Combinations of different 
drugs decrease high doses and associated adverse effects of any individual drug, 
counterbalance negative effects and facilitate additive positive effects by acting on 
different pathophysiological pathways; they probably also decrease costs or increase the 
cost/benefits ratio. The absence of indisputable evidences in Nephrology should not 
lead to the acceptance of attitudes of therapeutic nihilism while awaiting results from 
difficult confirmatory and definitive studies. Multi-interventional RCT and the 
development of reliable risk estratification scores seems distant aspirations; in the 
meantime, it would appear prudent at least not to increase the CVC burden in CKD 
patients, in compliance with the Hippocratic principle “first, do not harm”. As a matter 
of fact, it is known that the “absence of evidence” does not equate to “evidence of 
absence”122. All these considerations should prompt the design of new prospective 
RCTs to better define the potential direct relationship between CVC and outcomes and 
the institution of other better, earlier, and more cost-effective clinical actions in the 
field, including new studies with clinically relevant hard-outcomes (rather than 
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biochemical or radiological), and head-to-head comparisons that also take patient-
reported outcomes into account123.  
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Article highlights 
• CKD is linked to an extremely important and independent increase in 
mortality, and mineral and bone disorders (MBD) explain at least part of this 
disproportionate risk 
• Treatment of CKD-MBD requires an integral approach, addressing all 3 
components of the CKD-MBD triad (including the presence of CVC) 
• CKD-MBD and secondary hyperparahtyroidism are common and costly 
manifestations of CKD 
• Vitamin D deficiency is common both in the general population and in 
patients with CKD, and it is associated with poor outcomes 
• There is no proof that supplementation with vitamin D improves survival, 
although guidelines recommend treatment of vitamin D deficiency 
• Vitamin D receptor activators are used to reduce PTH secretion and have been 
associated with improved outcomes in observational studies and meta-
analyses, but not in RCTs 
• Selective activators of the vitamin D receptor (i.e. paricalcitol  
vs calcitriol) seem to have a wider therapeutic window (less hypercalcemic 
and hyperphosphatemic episodes) and have also been associated with 
improved survival in dialysis patients in retrospective studies  
• Calcimimetics provide a completely different means to control secondary 
hyperparathyroidism in dialysis patients, controlling PTH synthesis and 
secretion and decreasing calcium and phosphate levels.  
36 
 
• The ADVANCE and EVOLVE RCTs provide important clues towards 
improvement of hard outcomes in dialysis patients  
• Etelcalcetide represents a novel iv agonist of the calcium-sensing receptor 
• Combination of anti-parathyroid agents is a feasible clinical option 
• Low PTH levels (< 2 times the upper limit of normality for the assay) should 
be avoided since adynamic bone disease is associated to poor outcomes 
• Increasing trends in PTH levels should be treated and PTH levels > 9 times 
the upper limit of normality should be definitely avoided  
• Therapeutic nihilism while awaiting the results of new RCTs does not seem to 
be justified    
 
This box summarizes key points contained in the article 
 
CKD: chronic kidney disease; MBD: mineral and bone disorders; CKD-MBD: chronic 
kidney disease-mineral and bone disorder; CVC: cardiovascular calcification; PTH: 
parathyroid hormone; RCT: randomized clinical trial 
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Table 1. General comparison between vitamin D derivatives and cinacalcet 
 
 
ADVANTAGES DISADVANTAGES 
ACTIVE VITAMIN D 
Calcitriol 
Alfacalcidol 
Paricalcitol (SVDRA) 
Maxacalcitol (SVDRA) 
• Very good tolerance 
• Oral and intravenous routes 
• Decreases PTH synthesis 
• Improves bone 
• Can be given both  in dialysis 
and non-dialysis patients 
• Association with improved 
survival in retrospective 
studies and meta-analyses 
• Increased Ca, P and Ca x P 
level 
• Increased FGF-23 
• Cost and availability of 
SVDRA 
• Lack of hard end-point 
prospective RCTs 
CINACALCET • Oral (an intravenous 
calcimimetic is in Phase III) 
• Decreases PTH synthesis and 
secretion 
• Improves bone 
• Decreases Ca, Ca×P, and 
FGF-23 levels 
• May decrease P levels 
• May be given with high serum 
Ca and/or P levels 
• Hypocalcemia (rarely 
symptomatic) 
• Relatively poor tolerance 
(especially frequent nausea 
and vomiting among other 
secondary effects) 
• NOT indicated in non-
dialysis patients (only 
primary 
hyperparathyroidism and 
parathyroid carcinoma) 
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• Nominally significant 
attenuation of the progression 
of valvular and vascular 
calcification (RCT) 
• Nominally significant survival 
benefits (secondary adjusted 
predefined analysis of RCT) 
because of hypocalcemia 
and hyperphosphatemia 
• Cost and availability 
 
SVDRA: selective vitamin D receptor activators; Ca: calcium; P: phosphate; PTH: parathyroid 
hormone; FGF23: fibroblast growth factor 23; RCT: randomized clinical trial 
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Table 2. Negative and positive aspects of the EVOLVE study (EValuation Of 
Cinacalcet HCl therapy to Lower CardioVascular Events) 
NEGATIVE  
Nonsignificant primary composite endpoint by unadjusted ITT analysis 
Too many drop-ins (20% in the placebo group) 
Too many drop-outs (almost 2/3 in the cinacalcet group)  
Unacceptable loss of statistical power (re-estimated power, 54%) 
Very frequent secondary effects 
Complex statistics 
Inconclusive trial 
 
POSITIVE 
Clear positive tendencies with a single drug in the complex dialysis setting 
Nominally significant PRESPECIFIED analysis: 
  Adjusted multivariable analysis 
  Lag-censoring analysis 
  Inverse probability of censoring weighting (IPCW) 
Nominally significant decreases in heart failure, parathyroidectomy, clinically 
reported bone fractures, and calciphylaxis (secondary endpoints) 
Known and expected secondary effects   
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Table 3. Strategies to control gastrointestinal symptoms related to cinacalcet 
 
 
• Inform patients about the importance of controlling CKD-MBD and its impact on 
cardiovascular outcomes  
• Inform patients that although cinacalcet may cause GI effects, it is not an ulcer-
inducing drug 
• Give cinacalcet after the main meal or in the evening 
• Do not withdraw cinacalcet immediately if only mild/moderate symptoms are 
present  
• Start with the minimum dose and adjust the dose according to PTH and tolerance 
(combination with vitamin D may be helpful) 
• Decrease or fractionate the dose if symptoms appear after a dose escalation 
• Caution is advised with the use of antiemetics (including metoclopramide) in 
patients with hypocalcemia-related QT prolongation 
 
CKD-MBD: chronic kidney disease and mineral bone disease; GI: gastrointestinal; 
PTH: parathyroid hormone; QT: QT interval on electrocardiogram 
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Table 4. Considerations for adynamic bone disease 
 
 
• Avoid an excessive Ca load (Ca-based P-binders, active forms of vitamin D) and 
consider non-Ca based P-binders 
• Avoid an excessive PTH oversuppression (active forms of vitamin D, 
calcimimetics) and consider native vitamin D 
• Decrease Ca-dialysate content  
• Avoid trace metal exposure 
• Avoid bisphosphonates and other antiresorptive agents without a bone biopsy ruling 
out low-turnover bone disease 
• Potential for recombinant PTH and antisclerostin monoclonal antibodies (?) 
 
 
Ca: calcium; P: phosphate; PTH: parathyroid hormone 
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Table 5. Summary of the treatment of secondary hyperparathyroidism and CKD-
MBD 
 
Use knowledge of CVC to guide treatment of CKD-MBD, use drugs in combination, and 
individualize treatment. 
 
Phosphate (and/or FGF23) control: (P-binders) (see Part I)1  
 
• Achieve P levels as close to normality as possible with reasonable measures, 
including optimization of dialysis* 
• Avoid additives by all possible means, prioritize a balanced vegetarian vs animal 
dietary protein source and limit ↑ P/protein index foods 
• Prioritize P-binder prescription over unsupervised non-specific protein diet 
restriction  
• If very high serum PTH and P levels are present, consider the possibility that P may 
NOT be of intestinal origin. 
• Personalize choice of P-binder prescription depending on patient preferences, CKD 
stage (dialysis vs non-dialysis), presence/absence/degree of VC, concomitant 
therapies (i.e., VDRA, calcimimetics) and side effect profile (i.e., palatability, 
constipation, diarrhea)  
• Avoid Ca-based P-binders in patients with hypercalcemia, low PTH levels, and/or 
ABD. Avoid or limit Ca-based P-binders in diabetics, patients with VC, and patients 
treated with coumadin. 
43 
 
• Combination of P-binders is possible and inhibition of intestinal transporters may 
soon become an alternative or add-on therapy to improve clinical effectiveness. 
 
PTH control (specific anti-parathyroid treatment)  
• Aim for iPTH levels between 2 and 5 times the upper limit of normality and avoid 
extremes of risk (<2X or >9X).  
• Treat tendencies and do not respond to minor variations in PTH. 
• Initial drug selection may be based on CKD stage, Ca and P levels as well as on 
other aspects of CKD-MBD (e.g., CVC). 
• Cinacalcet is not approved for the treatment of secondary hyperparathyroidism in 
CKD stages 3-5 
• In CKD stage 5D, use vitamin D and calcimimetics in combination to improve 
efficacy with fewer secondary effects, eventually always considering the Ca and P 
levels 
• Selective VDRA (paricalcitol) may provide a wider therapeutic window, especially 
in those with a trend toward hypercalcemia or hyperphosphatemia, diabetic patients, 
and those prone to VC (experimental). 
• Cinacalcet is considered first-line treatment in hypercalcemic (and perhaps 
significantly hyperphosphatemic) dialysis patients.  
• I.V. etelcalcetide may improve compliance 
 
CKD-MBD: chronic kidney disease-mineral and bone disorder; P: phosphate; Ca: 
calcium; CVC: vascular calcification; ABD: adynamic bone disease; VDRA: vitamin D 
receptor activators; iPTH: intact parathyroid hormone; i.v.: intravenous; <2X->9X: less 
than 2 times or more than 9 times the upper limit of normality for the assay.  
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*Curiously, just in the summary of product characteristics of non-Ca based P binders it 
is stated that they are indicated for the control of hyperphosphatemia in adult patients 
with CKD not on dialysis only with serum P > 1.78 mmol/l (5.5 mg/dl). 
 
 
 
